secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001171843-21-007914
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics enters $75M senior revolving credit facility maturing 2026
-----------------------------------------------------------------------------

- Third Amendment to Credit Agreement increases revolving line to $75M, expandable to $150M.
- Maturity date extended to November 12, 2026; interest at BSBY + 0.25%-1.00%.
- Amended agreement governs leverage and interest coverage covenants; first-priority lien on assets.
- Bank of America serves as administrative agent; new lenders join the facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184321007914/0001171843-21-007914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184321007914/f8k_111521.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer